Sign in Register

Drug class

Oral treatments for Non-Small Cell Lung Cancer

The phrase "oral treatments for non-small cell lung cancer" is not a formal or discrete pharmacological drug class recognized by regulatory agencies like the FDA or NCI, but rather an administrative grouping describing orally administered antineoplastic agents indicated for non-small cell lung cancer. Read more about Oral treatments for Non-Small Cell Lung Cancer

42 drugs in this class 30 manufacturers

Related classes & indications

Alkylating AgentsOncology & immunomodulators · 192 prescription drugs Antirheumatic Agents (DMARDS, non-Biologic)Oncology & immunomodulators · 179 prescription drugs Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung CancerTop indication · 14 prescription drugs

Showing 28–36 of 42 drugs

Sort

LAZCLUZE (lazertinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION ·+1

JANSSEN BIOTECH, Inc.

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

AREVA PHARMACEU

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

ALEMBIC PHARMAC

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

SUN PHARMACEUTI

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

ZYDUS PHARMACEU

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

NOVADOZ PHARMAC

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

ARMAS PHARMACEU

ERLOTINIB HCL

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · ADENOCARCINOMA OF PANCREAS ·+2

TEVA USA

GEFITINIB

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 21 L858R SUBSTITUTION MUTATION ·+1

NATCO PHARMA US

Filter & compare in the drug finder → Opens the drug finder with Oral treatments for Non-Small Cell Lung Cancer preselected. Add indication or manufacturer filters there.

About Oral treatments for Non-Small Cell Lung Cancer.

The phrase "oral treatments for non-small cell lung cancer" is not a formal or discrete pharmacological drug class recognized by regulatory agencies like the FDA or NCI, but rather an administrative grouping describing orally administered antineoplastic agents indicated for non-small cell lung cancer.

This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, BRAF, RET, MET, KRAS, and HER2—as well as select oral chemotherapeutic agents.

These agents function mechanistically by selectively disrupting intracellular oncogenic signaling cascades or inhibiting cell division to arrest tumor proliferation and induce apoptosis.

Clinically, they are used across early-stage adjuvant, locally advanced, and metastatic non-small cell lung cancer regimens matching specific genomic or clinical profiles.

cancer.gov
The phrase "oral treatments for non-small cell lung cancer" is not a formal or discrete pharmacological drug class recognized by regulatory agencies like the FDA or NCI, but rather an administrative grouping describing orally administered antineoplastic agents indicated for non-small cell lung cancer
nih.gov
The phrase "oral treatments for non-small cell lung cancer" is not a formal or discrete pharmacological drug class recognized by regulatory agencies like the FDA or NCI, but rather an administrative grouping describing orally administered antineoplastic agents indicated for non-small cell lung cancer This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, B...
fda.gov
This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, BRAF, RET, MET, KRAS, and HER2—as well as select oral chemotherapeutic agents Clinically, they are used across early-stage adjuvant, locally advanced, and metastatic non-small cell lung cancer regimens matching specific genomic or clinical profiles
nih.gov
This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, BRAF, RET, MET, KRAS, and HER2—as well as select oral chemotherapeutic agents
nih.gov
These agents function mechanistically by selectively disrupting intracellular oncogenic signaling cascades or inhibiting cell division to arrest tumor proliferation and induce apoptosis